/PRNewswire/ Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for.
HC Wainwright reaffirmed their neutral rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright also issued estimates for Aadi Bioscience’s Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at ($0.73) […]
Soft Tissue Sarcoma Pipeline, FDA Approvals, Unmet Needs, Preclinical And Discovery Stage Product, And Companies 2024 (Updated) menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024 biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.